Andrew Cittadine net worth and biography

Andrew Cittadine Biography and Net Worth

Mr. Cittadine is an experienced healthcare executive and serial entrepreneur with a successful track record of identifying, founding, and building healthcare businesses from concept to commercialization to acquisition by Fortune Global 1000 firms. These include founding two successful diagnostic imaging companies, and leading both through acquisitions by Siemens and Olympus. His leadership experience also includes acting as startup CEO of critical care company which was acquired by Medtronic. He has managed manufacturing and quality systems implementation, execution of multi-center clinical trials, and regulatory clearances for new technologies in Europe and the US. Mr. Cittadine received his BA, BS, and MS from Stanford and an MBA from Northwestern’s Kellogg School of Management.

What is Andrew Cittadine's net worth?: The estimated net worth of Andrew Cittadine is at least $2.96 million as of June 20th, 2024. Mr. Cittadine owns 37,226 shares of Monopar Therapeutics stock worth more than $2,958,350 as of December 4th. This net worth approximation does not reflect any other assets that Mr. Cittadine may own. Additionally, Mr. Cittadine receives a salary of $416,700.00 as COO at Monopar Therapeutics. Learn More about Andrew Cittadine's net worth.
How old is Andrew Cittadine?: Mr. Cittadine is currently 51 years old. There are 3 older executives and no younger executives at Monopar Therapeutics. The oldest executive at Monopar Therapeutics is Dr. Patrice P. Rioux M.D., Ph.D., Acting Chief Medical Officer, who is 73 years old. Learn More on Andrew Cittadine's age.
What is Andrew Cittadine's salary?: As the COO of Monopar Therapeutics Inc., Mr. Cittadine earns $416,700.00 per year. The highest earning executive at Monopar Therapeutics is Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc, Co-Founder, CEO, President & Director, who commands a salary of $710,500.00 per year. Learn More on Andrew Cittadine's salary.
How do I contact Andrew Cittadine?: The corporate mailing address for Mr. Cittadine and other Monopar Therapeutics executives is 1000 SKOKIE BLVD SUITE 350, WILMETTE IL, 60091. Monopar Therapeutics can also be reached via phone at 847-388-0349 and via email at [email protected]. Learn More on Andrew Cittadine's contact information.
Has Andrew Cittadine been buying or selling shares of Monopar Therapeutics?: Andrew Cittadine has not been actively trading shares of Monopar Therapeutics during the last quarter. Most recently, on Thursday, June 20th, Andrew Cittadine bought 4,101 shares of Monopar Therapeutics stock. The stock was acquired at an average cost of $3.70 per share, with a total value of $15,173.70. Following the completion of the transaction, the chief operating officer now directly owns 37,226 shares of the company's stock, valued at $137,736.20. Learn More on Andrew Cittadine's trading history.
Are insiders buying or selling shares of Monopar Therapeutics?: In the last twelve months, insiders at the sold shares 5 times. They sold a total of 626,067 shares worth more than $37,866,916.69. The most recent insider tranaction occured on September, 24th when Major Shareholder Tactic Pharma Llc sold 550,229 shares worth more than $35,000,066.69. Insiders at Monopar Therapeutics own 20.5% of the company. Learn More about insider trades at Monopar Therapeutics.
Information on this page was last updated on 9/24/2025.

Andrew Cittadine Insider Trading History at Monopar Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/20/2024	Buy	4,101	$3.70	$15,173.70	37,226
6/17/2024	Buy	2,400	$4.50	$10,800.00	30,724
6/13/2024	Buy	2,400	$4.55	$10,920.00	25,924
6/3/2024	Buy	2,400	$3.80	$9,120.00	21,124
5/31/2024	Buy	2,400	$3.20	$7,680.00	18,724
5/29/2024	Buy	2,400	$3.20	$7,680.00	13,924
11/14/2022	Buy	1,210	$15.00	$18,150.00	2,847

Andrew Cittadine Buying and Selling Activity at Monopar Therapeutics

Monopar Therapeutics Company Overview

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Today's Range

Now: $79.47

$75.47

$79.90

50 Day Range

MA: $85.23

$75.90

$102.05

2 Week Range

Now: $79.47

$20.16

$105.00

Volume

155,064 shs

Average Volume

168,105 shs

Market Capitalization

$530.86 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.46

Andrew Cittadine Biography and Net Worth

What is Andrew Cittadine's net worth?

How old is Andrew Cittadine?

What is Andrew Cittadine's salary?

How do I contact Andrew Cittadine?

Has Andrew Cittadine been buying or selling shares of Monopar Therapeutics?

Are insiders buying or selling shares of Monopar Therapeutics?